Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AGVaccine Specialist AFFiRiS AG successfully completes Financing Round
• € 10m additional capital raised
• Supervisory Board appoints Oliver Siegel as Chief Executive Officer
• Prof. Dr. Christoph Huber elected to Supervisory Board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the Supervisory Board as of 18 May 2015 and replaces Dr. Walter Schmidt who has decided to leave the Supervisory Board. Mag. Vera Bürger and Claudia Juno have been appointed by the employees to join the Supervisory Board.
In an extraordinary shareholders meeting on 18 May 2015 the shareholders of the company have agreed to a capital increase of € 10m. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – and the MIG Funds represented by MIG Verwaltungs AG. The shareholders also elected Prof. Dr. Christoph Huber as member of the Supervisory Board. He will replace Dr. Walter Schmidt who has decided to leave the Supervisory Board. Walter Schmidt co-founded AFFiRiS eleven years ago and profoundly influenced the company until his resignation from operational responsibilities this past January.
Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS said: "Walter Schmidt has been instrumental in shaping AFFiRiS. His business acumen and his entrepreneurship have been critical in establishing the AFFITOME®-technology as a leading platform for active immune therapy in the prevention and therapy of chronic illnesses. I am pleased to welcome Prof. Christoph Huber to the Supervisory Board. His outstanding scientific achievements in the field of immunology and his entrepreneurial spirit as founder of various successful biotech companies will be of great value to the future development of AFFiRiS." The Supervisory Board appointed Oliver Siegel (49) as Chief Executive Officer and Dr. Arne von Bonin (51) as Chief Scientific Officer (CSO).
The new capital allows the company to further advance its AFFITOME®-technology for the prevention and therapy of chronic illnesses. Oliver Siegel comments these developments: "The successful capital increase demonstrates the continued support from our investors in the technology and the scientific team. The ongoing support will be essential to the successful development of our vaccine technology as platform technology in a number of indications."
Recently, AFFIRIS presented Phase 1 data on its Parkinson’s vaccine candidate PD01. PD01A was the first α-synuclein targeting drug candidate that successfully completed a phase 1 study. α-synuclein is a protein which plays a role in the pathological processes of neurodegenerative diseases such as Parkinson’s. The program enjoys the support from The Michael J. Fox Foundation, the world’s largest nonprofit funder of Parkinson’s research.
About AFFiRiS AG:
On the basis of its proprietary patented AFFITOME®-technology, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Currently, its clinical pipeline consists of 3 drug candidates against Parkinson’s, MSA and Hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma as well as Huntington's disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 120m to date, half of which comes from license income and government grants. AFFiRiS currently employs 57 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
Contact AFFiRiS AG:
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 300
PR&D – Public Relations for Research & Education
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG here
News-ID: 311533 • Views: 110486
More Releases from AFFiRiS AG
AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised • Strengthened management team, Günther Staffler appointed as Chief Technology Officer • Noel Barrett appointed as additional member of the supervisory board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016. In
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing Vienna, November 18, 2009: AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of
More Releases for Supervisory
SEEBURGER AG - Continuity in the Supervisory Board Ensured
Annual general meeting confirms the three members of the supervisory board in office for a further five years 2020/11/04 Bretten, Germany - The members of the SEEBURGER Supervisory Board with the Chairman Professor Dr. Simone Zeuchner, her deputy Katrin Seeburger and Ralph Jacoby were unanimously re-elected at this year's Annual General Meeting in October. The term of office of the existing Supervisory Board was thus extended by a further five years,
Supervisory Control and Data Acquisition (SCADA) Market | supervisory control an …
Supervisory control and data acquisition system primarily collects data from running industrial processes and utilize them to recognize any anomaly in the production process. Global SCADA Market is primarily driven by increase in investments, for infrastructure development, in the emerging markets. The renewed interest in shale gas extraction has also driven the SCADA market forward. In the electrical power sector, SCADA systems are being deployed in countries like India and
GmbH and establishing a supervisory board later on
If a GmbH decides to set up a supervisory board at a later stage, this needs to be certified by a notary and entered into the commercial register even if there is an opening clause. GRP Rainer Lawyers and Tax Advisors in Cologne, Berlin, Bonn, Düsseldorf, Frankfurt, Hamburg, Munich, Stuttgart and London conclude: A Gesellschaft mit beschränkter Haftung (GmbH for short), a type of German private limited company, is not typically
KWG announces changes in Supervisory Board
Hamburg - 12 April 2013 - KWG Kommunale Wohnen AG, the long-term oriented property holding company of German residential real estate, announces changes in the company's Supervisory Board following the acquisition of a majority stake in the company by conwert Immobilien Invest SE. In this context Franz-Josef Gesinn, Thies-Martin Brandt, Bjoern Engholm, Hans-Michael Porwoll und Patrik Zeigherman resigned from the Supervisory Board in mutual agreement. The Supervisory Board's Chairman Prof.
Gert-Maria Freimuth intents move into Supervisory Board
Berlin, 14 February 2013 MBB Industries AG (ISIN DE000A0ETBQ4), a family-owned, medium-sized corporation has scheduled changes in its Managing and Supervisory Board for its Annual General Meeting on 17 June 2013. After 17 years of executive mandates, Gert-Maria Freimuth, member of the Managing Board and major shareholder of MBB Industries AG has informed both Managing and Supervisory Board of his intention to step down as Chief Investment Officer at the Annual
euroscript’s supervisory board appoints Philippe Gaillard as Chief Sales Offic …
Bertrange, 10 November 2009 - We have the pleasure to announce that Philippe Gaillard joined euroscript International S.A. as Chief Sales Officer on November 1, 2009. He will be responsible for group sales, international business development as well as partner and contract management. Philippe succeeds Benoît Laxenaire who will maintain his successful focus on major account development as Vice President Sales. Benoît will strengthen the French management team by joining the French